These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 23444216)
1. Aflibercept. Ciombor KK; Berlin J; Chan E Clin Cancer Res; 2013 Apr; 19(8):1920-5. PubMed ID: 23444216 [TBL] [Abstract][Full Text] [Related]
2. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence. Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671 [TBL] [Abstract][Full Text] [Related]
3. Aflibercept: A Review in Metastatic Colorectal Cancer. Syed YY; McKeage K Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913 [TBL] [Abstract][Full Text] [Related]
4. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Van Cutsem E; Joulain F; Hoff PM; Mitchell E; Ruff P; Lakomý R; Prausová J; Moiseyenko VM; van Hazel G; Cunningham D; Arnold D; Schmoll HJ; Ten Tije AJ; McKendrick J; Kröning H; Humblet Y; Grávalos C; Le-Guennec S; Andria M; Dochy E; Vishwanath RL; Macarulla T; Tabernero J Target Oncol; 2016 Jun; 11(3):383-400. PubMed ID: 26706237 [TBL] [Abstract][Full Text] [Related]
5. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147 [TBL] [Abstract][Full Text] [Related]
6. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. Ruff P; Van Cutsem E; Lakomy R; Prausova J; van Hazel GA; Moiseyenko VM; Soussan-Lazard K; Dochy E; Magherini E; Macarulla T; Papamichael D J Geriatr Oncol; 2018 Jan; 9(1):32-39. PubMed ID: 28807738 [TBL] [Abstract][Full Text] [Related]
7. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. Ruff P; Ferry DR; Lakomỳ R; Prausová J; Van Hazel GA; Hoff PM; Cunningham D; Arnold D; Schmoll HJ; Moiseyenko VM; McKendrick JJ; Ten Tije AJ; Vishwanath RL; Bhargava P; Chevalier S; Macarulla T; Van Cutsem E Eur J Cancer; 2015 Jan; 51(1):18-26. PubMed ID: 25466509 [TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. Folprecht G; Pericay C; Saunders MP; Thomas A; Lopez Lopez R; Roh JK; Chistyakov V; Höhler T; Kim JS; Hofheinz RD; Ackland SP; Swinson D; Kopp M; Udovitsa D; Hall M; Iveson T; Vogel A; Zalcberg JR Ann Oncol; 2016 Jul; 27(7):1273-9. PubMed ID: 27091810 [TBL] [Abstract][Full Text] [Related]
9. A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. Yoshino T; Yamazaki K; Yamaguchi K; Doi T; Boku N; Machida N; Onozawa Y; Asayama M; Fujino T; Ohtsu A Invest New Drugs; 2013 Aug; 31(4):910-7. PubMed ID: 23179335 [TBL] [Abstract][Full Text] [Related]
10. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Tabernero J; Van Cutsem E; Lakomý R; Prausová J; Ruff P; van Hazel GA; Moiseyenko VM; Ferry DR; McKendrick JJ; Soussan-Lazard K; Chevalier S; Allegra CJ Eur J Cancer; 2014 Jan; 50(2):320-31. PubMed ID: 24140268 [TBL] [Abstract][Full Text] [Related]
11. Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Van Cutsem E; Paccard C; Chiron M; Tabernero J Clin Cancer Res; 2020 Feb; 26(3):717-725. PubMed ID: 31727675 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. Lambrechts D; Thienpont B; Thuillier V; Sagaert X; Moisse M; Peuteman G; Pericay C; Folprecht G; Zalcberg J; Zilocchi C; Margherini E; Chiron M; Van Cutsem E Br J Cancer; 2015 Sep; 113(7):1027-34. PubMed ID: 26355232 [TBL] [Abstract][Full Text] [Related]
13. [Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer]. André T; Chibaudel B Bull Cancer; 2013 Oct; 100(10):1023-5. PubMed ID: 24047539 [TBL] [Abstract][Full Text] [Related]
14. A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. Chau I; Joulain F; Iqbal SU; Bridgewater J BMC Cancer; 2014 Aug; 14():605. PubMed ID: 25142418 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer. Chong DQ; Manalo M; Imperial M; Teo P; Yong G; Ng M; Tan IB; Choo SP; Chua C Asia Pac J Clin Oncol; 2016 Sep; 12(3):275-83. PubMed ID: 27075236 [TBL] [Abstract][Full Text] [Related]
16. Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. Denda T; Sakai D; Hamaguchi T; Sugimoto N; Ura T; Yamazaki K; Fujii H; Kajiwara T; Nakajima TE; Takahashi S; Otsu S; Komatsu Y; Nagashima F; Moriwaki T; Esaki T; Sato T; Itabashi M; Oki E; Sasaki T; Sunaga Y; Ziti-Ljajic S; Brillac C; Yoshino T Cancer Sci; 2019 Mar; 110(3):1032-1043. PubMed ID: 30657223 [TBL] [Abstract][Full Text] [Related]
17. Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. Joulain F; Proskorovsky I; Allegra C; Tabernero J; Hoyle M; Iqbal SU; Van Cutsem E Br J Cancer; 2013 Oct; 109(7):1735-43. PubMed ID: 24045663 [TBL] [Abstract][Full Text] [Related]
18. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer. Chung C; Pherwani N Am J Health Syst Pharm; 2013 Nov; 70(21):1887-96. PubMed ID: 24128964 [TBL] [Abstract][Full Text] [Related]
19. Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer. Satake H; Ando K; Oki E; Shimokawa M; Makiyama A; Saeki H; Tsuji A; Mori M BMC Cancer; 2020 Nov; 20(1):1116. PubMed ID: 33203393 [TBL] [Abstract][Full Text] [Related]
20. Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302). Lapeyre-Prost A; Pernot S; Sigrand J; Le Malicot K; Mary F; Aparicio T; Dahan L; Caroli-Bosc FX; Lecomte T; Doat S; Marthey L; Desrame J; Lepage C; Taieb J Clin Colorectal Cancer; 2020 Dec; 19(4):285-290. PubMed ID: 32921581 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]